Thursday, November 19, 2026
Village Voice News
ADVERTISEMENT
  • Home
  • News
  • Sports
  • Editorial
  • Letters
  • Global
  • Columns
    • Eye On Guyana
    • Hindsight
    • Lincoln Lewis Speaks
    • Future Notes
    • Blackout
    • From The Desk of Roysdale Forde SC
    • Diplomatic Speak
    • Mark’s Take
    • In the village
    • Mind Your Business
    • Bad & Bold
    • The Voice of Labour
    • The Herbal Section
    • Politics 101 with Dr. David Hinds
    • Talking Dollars & Making Sense
    • Book Review 
  • Education & Technology
  • E-Paper
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Sports
  • Editorial
  • Letters
  • Global
  • Columns
    • Eye On Guyana
    • Hindsight
    • Lincoln Lewis Speaks
    • Future Notes
    • Blackout
    • From The Desk of Roysdale Forde SC
    • Diplomatic Speak
    • Mark’s Take
    • In the village
    • Mind Your Business
    • Bad & Bold
    • The Voice of Labour
    • The Herbal Section
    • Politics 101 with Dr. David Hinds
    • Talking Dollars & Making Sense
    • Book Review 
  • Education & Technology
  • E-Paper
  • Contact Us
No Result
View All Result
Village Voice News
No Result
View All Result
Home Global

COVID-19 treatment Molnupiravir starts to sell in China

Admin by Admin
January 27, 2023
in Global
Antiviral molnupiravir Photo:VCG

Antiviral molnupiravir Photo:VCG

0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

The oral antiviral COVID-19 medicine LAGEVRIO (molnupiravir capsule) has been on sale in many places across China, with different medical insurance reimbursement ratios.

Molnupiravir, developed by US pharmaceutical giant Merck Sharp & Dohme (MSD), among other COVID treatments including Paxlovid and Azvudine tablets, is currently covered by China’s public health insurance until March 31.

READ ALSO

AFRICA | Miami’s Empty Chair: Africa’s Only G20 Nation Shut Out on the Caribbean’s Doorstep

New study validates global clinical obesity standards beyond BMI

A hospital in Xuzhou, East China’s Jiangsu Province issued its first prescription pad of molnupiravir on January 18. According to the regulation of local medical insurance, 75 percent of the cost could be reimbursed in the outpatient service and there is no threshold limit.

On January 17, the first batch of molnupiravir capsules was transported to the Southwest Hospital in Chongqing. Meanwhile, the medicine has come to nearly 80 public hospitals in Shanghai.

The Healthcare Security Bureau of Shenzhen Municipality said that from January 8 to March 31, the hospitalization expenses of patients infected with the new coronavirus will be fully covered by the medical insurance and the monogravir capsules have been temporarily included in the medical insurance with 85 percent of the cost to be potentially  that can be reimbursed.

On December 29, 2022, the State Food and Drug Administration conditionally approved the import registration of monoravir capsules. The 10th edition of China’s COVID-19 control protocols released on January 6 added the drug to the content of antiviral treatments. Monogravir capsules are the third oral antiviral COVID-19 medicine approved in China after Paxlovid and Azvudine tablets.

In September last year, China’s large-scale vaccine producer Sinopharm and MSD signed a cooperation framework agreement, under which Sinopharm would be an exclusive dealer of molnupiravir in China.

In November, a subsidiary of Sinopharm signed an agreement with MSD to be responsible for the import and distribution of molnupiravir in the Chinese mainland.

Molnupiravir is a small-molecule oral antiviral drug that can be used for treating mild-to-moderate COVID-19 patients who face the risk of developing more serious symptoms, including patients who are elderly, obese or have chronic conditions like coronary heart disease or diabetes. Patients should use the medicine strictly according to the instructions under the guidance of a doctors.

Global Times

ShareTweetSendShareSend

Related Posts

A composite image of US President Donald Trump and South African President Cyril Ramaphosa.
Global

AFRICA | Miami’s Empty Chair: Africa’s Only G20 Nation Shut Out on the Caribbean’s Doorstep

by Admin
November 18, 2026

Washington has struck South Africa from the Miami summit list and seated Poland among the members. For a Caribbean that...

Read moreDetails
China Flag
Global

New study validates global clinical obesity standards beyond BMI

by Admin
November 18, 2026

WUHAN -- Am I obese or not? This is a question asked worldwide, and body mass index (BMI) has long...

Read moreDetails
Home Alone (Google photo)
Global

Home Alone Returns This Christmas with a Touch of Sadness

by Admin
November 18, 2026

By Mark DaCosta-This festive season, a film that has long signalled the start of Christmas in homes across our nation...

Read moreDetails
Next Post

IAAD condemns the government’s planned action to dispossess land cooperatives societies of lands.


EDITOR'S PICK

How Five Sugar Workers Became the Enmore Martyrs

June 21, 2026
President Irfaan Ali

Behind the ‘One Guyana’ Campaign Lies a Call for Structural Reform

May 12, 2026

‘Blame it on the scanners’

November 6, 2020

Unity in Heritage: Why Our National Motto Must Endure

January 18, 2026

© 2024 Village Voice

No Result
View All Result
  • Home
  • News
  • Sports
  • Editorial
  • Letters
  • Global
  • Columns
    • Eye On Guyana
    • Hindsight
    • Lincoln Lewis Speaks
    • Future Notes
    • Blackout
    • From The Desk of Roysdale Forde SC
    • Diplomatic Speak
    • Mark’s Take
    • In the village
    • Mind Your Business
    • Bad & Bold
    • The Voice of Labour
    • The Herbal Section
    • Politics 101 with Dr. David Hinds
    • Talking Dollars & Making Sense
    • Book Review 
  • Education & Technology
  • E-Paper
  • Contact Us

© 2024 Village Voice